Literature DB >> 35279761

Circ-TFF1 Promotes Breast Cancer Progression Through the miR-129-2-3p/IRAK1 Axis.

Yu Zhao1, Fan Ren2, Xiaoxin Wang2, Yangkai Liu3.   

Abstract

Breast cancer (BC) is a common malignant tumor, and circular RNA-trefoil factor 1 (circ-TFF1; hsa_circ_0061825) has been found to be highly expressed in BC tissues and cells and is associated with the poor prognosis of BC patients. However, the interaction between circ-TFF1 and microRNA in BC has not been studied. Quantitative real-time PCR was used to detect the expression of circ-TFF1, miR-129-2-3p, and interleukin (IL)-1 receptor-associated kinase 1 (IRAK1). Through the detection of cell proliferation, migration, invasion, tube formation, and apoptosis, cell function was assessed. The expression levels of angiogenesis-related proteins were detected by western blot. The interaction between miR-129-2-3p and circ-TFF1 or IRAK1 was verified by dual-luciferase reporter assay and RNA immunoprecipitation assay. Xenotransplantation experiments were used to confirm the function of circ-TFF1 in vivo. Circ-TFF1 and IRAK1 were significantly high expressed in BC tissues and cells. Silencing of circ-TFF1 reduced the proliferation, migration, invasion and tube formation, while increased the apoptosis of MDA-MB-361 and SK-Br-3 cells. MiR-129-2-3p was a target of circ-TFF1. Silencing of circ-TFF1 inhibited the malignant behavior of BC cells by releasing miR-129-2-3p. In addition, IRAK1 was a target of miR-129-2-3p. Overexpression of IRAK1 partially restored the inhibitory effect of miR-129-2-3p on cell progression. Animal experiments confirmed the anti-tumor effect of circ-TFF1 knockdown in vivo. Circ-TFF1 regulated the expression of IRAK1 by sponging miR-129-2-3p, thereby, promoting the development of BC. These data provided a novel targeted therapy for BC.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Breast cancer; Circ-TFF1; IRAK1; miR-129-2-3p

Year:  2022        PMID: 35279761     DOI: 10.1007/s10528-022-10209-4

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  6 in total

1.  In vivo and in vitro impact of miR-31 and miR-143 on the suppression of metastasis and invasion in breast cancer.

Authors:  Sorour Soheilyfar; Zahra Velashjerdi; Yasamin Sayed Hajizadeh; Nazila Fathi Maroufi; Zahra Amini; Afshin Khorrami; Saba Haj Azimian; Alireza Isazadeh; Sina Taefehshokr; Nima Taefehshokr
Journal:  J BUON       Date:  2018 Sep-Oct       Impact factor: 2.533

Review 2.  Breast cancer statistics, 2013.

Authors:  Carol DeSantis; Jiemin Ma; Leah Bryan; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-10-01       Impact factor: 508.702

3.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

4.  miR-146a Enhances the Sensitivity of Breast Cancer Cells to Paclitaxel by Downregulating IRAK1.

Authors:  Yalun Li; Weilong Li; Jun Lin; Chunjing Lv; Guangdong Qiao
Journal:  Cancer Biother Radiopharm       Date:  2020-12-01       Impact factor: 3.632

5.  miR-146a-5p targets interleukin-1 receptor-associated kinase 1 to inhibit the growth, migration, and invasion of breast cancer cells.

Authors:  Jing-Pei Long; Li-Feng Dong; Fang-Fang Chen; Yang-Fan Fan
Journal:  Oncol Lett       Date:  2018-11-28       Impact factor: 2.967

6.  Circular RNA hsa_circ_0061825 (circ-TFF1) contributes to breast cancer progression through targeting miR-326/TFF1 signalling.

Authors:  Gaofeng Pan; Anwei Mao; Jiazhe Liu; Jingfeng Lu; Junbin Ding; Weiyan Liu
Journal:  Cell Prolif       Date:  2020-01-21       Impact factor: 6.831

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.